A new study has identified key mutations that can direct the conditioning regimen prior to an allogenic hematopoietic stem cell transplant (SCT) in patients with myelodysplastic syndrome (MDS), leading to a better response.
Identifying the presence of key mutations can help direct the conditioning regimen prior to an allogenic hematopoietic stem cell transplant (SCT) in patients with myelodysplastic syndrome (MDS), leading to a better response. These are the findings of a new research study published by scientists at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
The researchers performed targeted mutational analysis on 1514 patients with MDS—between 6 months and 70 years old—prior to their transplantation between 2005 and 2014. Donor stem cell transplantation is the only treatment choice in patients who are at a high risk of dying with standard treatments, and complications associated with the transplant itself or disease relapse are usually responsible, according to R. Coleman Lindsley, MD, PhD, lead author on the paper.
“As physicians, one of our major challenges is to be able to predict which patients are most likely to benefit from a transplant,” Lindsley said in a statement. “Improving our ability to identify patients who are most likely to have a relapse or to experience life-threatening complications from a transplant could lead to better pre-transplant therapies and strategies for preventing relapse.”
To pinpoint the specific genes that could influence patient response to SCT, researchers analyzed the patient blood samples and identified TP53 as the single most important gene responsible for determining characteristics of a patient’s MDS, and was present in 19% of patients in this cohort. Mutations in TP53 were a definite indicator of quicker relapse and a shorter survival following transplant (P <.001 for both), irrespective of the prior conditioning regimen that a patient would have received—standard treatment (chemotherapy and/or radiation therapy) or reduced-intensity conditioning (lower doses of chemotherapy and/or radiation therapy).
Among patients (40 years or older) who did not have TP53 mutations, the RAS pathway proteins played an important role in predicting survival posttransplant. Patients who had mutations had a shorter time to relapse than those who did not (P = .004). Similarly, patients with JAK2 mutations had a shorter survival than those without (P = .001), but these patients did not relapse. As opposed to TP53 mutations, the effect of RAS mutations was only evident under the reduced-intensity preconditioning regimen, indicating that these patients could perform better under a high-intensity regimen.
The researchers observed heterozygous mutations in the Shwachman—Diamond syndrome–associated SBDS gene in tandem with TP53 mutations in 4% of young adult patients (18 to 40 years), along with a poor prognosis following transplantation. They also found that mutations in TP53 and in PPM1D were more common among patients who were treatment-naïve.
“In deciding whether a stem cell transplant is appropriate for a patient with MDS, it’s always necessary to balance the potential benefit with the risk of complications,” Lindsley said. “Our findings offer physicians a guide—based on the genetic profile of the disease and certain clinical factors—to identifying patients for whom a transplant is appropriate, and the intensity of treatment most likely to be effective.”
Reference
Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547. doi: 10.1056/NEJMoa1611604.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More